knowledge -WSS

knowledge

author：explore 2025-08-12 08:25:38 - browse：9494

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Keeping primary care docs in field isn't impossible, says AAFP CEO

hotspot

WSS

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

The White House hikes tariffs on plastic syringes made in China

Medicare drug price negotiation hasn't dried up venture capital

The White House hikes tariffs on plastic syringes made in China

HHS suspends federal funding for EcoHealth Alliance

Prime Medicine, Myeloid Therapeutics clash over genome

knowledge

knowledge

explore

New air purifier tech could be key to improving indoor air quality

Boston hospital trains restaurant workers on naloxone for overdoses

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Medicare proposal to cover medical devices draws a mixed reaction

Lilly’s weekly insulin works as well as daily products, new studies show

BioMarin wins approval for gene therapy to treat hemophilia A

Cherokee Nation medical school graduates its first class

Dobbs anniversary: the lost opportunity of abortion as health care

Editas, Vertex strike deal on CRISPR

knowledge

Oak Street deal isn't the answer to health care's woes

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Readout Newsletter: The latest on Moderna, Apellis, and Merck

David Ricks of Eli Lilly: best biopharma CEO of 2023

What STAT readers think about the FDA and patient advocacy

How to keep neuroscience’s past racism from being its future

focus

leisure time

hotspot

Wikipedia